News

Discover how TimeTeller, the latest venture from BIH Digital Health Accelerator, has developed a groundbreaking non-invasive method to determine your individual circadian rhythm. By analyzing saliva samples through a combination of experimental analysis and mathematical models, TimeTeller provides personalized recommendations for optimizing daily activities such as training, sleep, and medication intake. Find out how this technology aims to improve well-being, enhance medical treatments, and revolutionize the way we approach health. [Read more]

Every individual has his or her own internal clock. It determines lifestyle to an important extent. Angela Relógio and her research group at Charité have developed a method for detecting the beat of the inner clock by saliva test. This could also help people who have cancer, she says.

Here the full interview with Prof. Dr. Angela Relógio.

Check out the News article in the Berliner Zeitung - Zur falschen Zeit ins Bett? Neuartige Methode zur Bestimmung der inneren Uhr, Torsten Harmsen, 24.05.2023 on Berlin researchers that developed a method that anyone can use to determine: When is the right time for sleep, training and medication?

The Berlin Institute of Health at Charité issued a press release acknowledging TimeTeller as one of its successful spin-offs in healthcare.

Check out the original sources linked down below:
Berlin Institute of Health - TimeTeller bestimmt die innere Uhr: Zehnte Ausgründung des BIH Digital Health Accelerator verrät den richtigen Zeitpunkt für Training, Schlaf und Medikamentengabe, Dr. Stefanie Seltmann, 23.05.2023.

TimeTeller has announced the publication of a scientific article titled "TimeTeller for timing health: The potential of circadian medicine to improve performance, prevent disease and optimize treatment" in Frontiers in Digital Health (doi.org/10.3389/fdgth.2023.1157654). The publication highlights the potential of circadian medicine in enhancing health and performance, and optimizing treatment timing.

In short:

Circadian medicine is the study of the effects of time on health and disease. The circadian clock, our endogenous time generating system, regulates behavioral, physiological, and cellular processes. Disruptions of the clock are linked to an increased risk of various diseases, including obesity, diabetes, cardiovascular diseases, and cancer.

The lack of non-invasive tools for characterizing the circadian clock has limited the potential of circadian medicine. TimeTeller is a non-invasive molecular/digital tool for the characterization of circadian rhythms and prediction of daily routines, including treatment timing. By aligning an individual's circadian clock with optimal times for performing daily routines, physical and mental performance, and also the effectiveness of certain therapies can be improved.

The article suggests that the utility of TimeTeller can best be exploited in data-driven, personalized medicine use cases, using health information across lifestyle, care, and research settings. The potential of circadian medicine to improve performance, prevent disease, and optimize treatment is vast, and TimeTeller's innovative approach could help unlock its full potential.

TimeTeller® has been selected for funding by the InnoRampUp program by the IFB Hamburg in 2023. The funding will allow TimeTeller® to continue developing an in vitro diagnostic (IVD) technology to profile the circadian rhythm and explore its applications like time treatment in various indications, health prevention or to enhance athletic performance.

The InnoRampUp program aims to support technologically innovative startups in Hamburg with grants of up to €150,000 in the start-up phase. The program focuses on startups that have a realistic chance of achieving economic success and are led by a convincing team with an entrepreneurial spirit.

"We are thrilled to have been selected for funding by the InnoRampUp program," said Prof. Dr. Angela Relógio, CEO of TimeTeller®. "This support will allow us to continue developing our innovative technology and bring it to the market, ultimately helping to improve patient outcomes and advance science.”

This funding will enable TimeTeller® to make significant advances in the development of its IVD technology, positioning the company as a leader in the field of time-based measurements for clinical studies.

TimeTeller®, a Hamburg-based start-up, was founded in March 2023 by Prof. Dr. Angela Relógio, Ascenion, a representative of the Charité, and Dr. Benjamin Dose, and has announced its official launch. TimeTeller® is a spin-off from the Charité Berlin, where the TimeTeller® Project was part of the "Inventors for Health (I4H) Programme,“ and the “Digital Health Accelerator” (DHA) programms aimed at promoting the development of breakthrough medical innovations and training a new generation of inventors.

"We are thrilled to launch TimeTeller® and are one step closer to bring TimeTeller® to the market," said Prof. Dr. Angela Relógio, co-founder and CEO of TimeTeller®. "Our mission is to improve patient outcomes by developing time-based medicine solutions that are tailored to each patient's individual needs."

TimeTeller®'s technology is based on a patented algorithm that analyzes a patient's circadian rhythm, to determine the optimal timing for medication administration. This personalized approach to medicine has the potential to significantly improve treatment outcomes and reduce side effects.

"We believe that personalized medicine is the future of healthcare, and we are excited to be at the forefront of this revolution," said Dr. Benjamin Dose, co-founder of TimeTeller®. "Our technology has the potential to transform the way we approach treatment and improve the lives of millions of patients worldwide."

TimeTeller® is set to continue ongoing clinical trials in the coming months and plans to validate its product in late 2023.